CONMED (CNMD) to Release Quarterly Earnings on Wednesday

CONMED (NYSE:CNMD) is expected to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect CONMED to post earnings of $1.10 per share and revenue of $337.5960 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, April 29th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. CONMED had a return on equity of 13.84% and a net margin of 4.00%.The firm had revenue of $317.05 million during the quarter, compared to analysts’ expectations of $310.64 million. During the same period in the previous year, the firm posted $0.95 EPS. CONMED’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Price Performance

Shares of NYSE CNMD opened at $43.45 on Tuesday. The stock’s 50-day moving average is $36.60 and its two-hundred day moving average is $38.39. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.29 and a quick ratio of 1.04. CONMED has a 1-year low of $31.44 and a 1-year high of $56.63. The company has a market cap of $1.31 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 3.16 and a beta of 0.93.

Analyst Upgrades and Downgrades

CNMD has been the subject of several recent research reports. Bank of America reiterated an “underperform” rating and issued a $40.00 price objective on shares of CONMED in a research note on Monday, June 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of CONMED in a research note on Thursday, June 4th. Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. cut their price target on CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Five research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, CONMED currently has a consensus rating of “Reduce” and an average target price of $38.80.

Institutional Trading of CONMED

Several institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock valued at $857,000 after purchasing an additional 2,357 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of CONMED by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock valued at $1,108,000 after buying an additional 800 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of CONMED by 5.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after buying an additional 4,565 shares during the period. Intech Investment Management LLC boosted its stake in shares of CONMED by 34.6% during the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock worth $1,359,000 after buying an additional 5,780 shares during the period. Finally, Creative Planning purchased a new position in shares of CONMED during the second quarter worth about $310,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.